

US011554229B2

# (12) United States Patent Djupesland et al.

(10) Patent No.: US 11,554,229 B2

(45) **Date of Patent: Jan. 17, 2023** 

(54) NASAL ADMINISTRATION

(71) Applicant: **OPTINOSE AS**, Oslo (NO)

(72) Inventors: **Per Gisle Djupesland**, Oslo (NO);

Ramy A. Mahmoud, Skillman, NJ (US); John Messina, Downingtown, PA

(US)

(73) Assignee: OptiNose Inc., Yardley, PA (US)

(\*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 699 days.

(21) Appl. No.: 14/315,132

(22) Filed: Jun. 25, 2014

(65) **Prior Publication Data** 

US 2015/0144129 A1 May 28, 2015

### Related U.S. Application Data

(63) Continuation-in-part of application No. 14/226,287, filed on Mar. 26, 2014, now abandoned.

(Continued)

(51) **Int. Cl. A61M 15/08** 

A61M 16/00

(2006.01) (2006.01)

(Continued)

(52) U.S. Cl.

CPC ....... A61M 15/08 (2013.01); A61M 15/0098 (2014.02); A61M 16/0057 (2013.01);

(Continued)

(58) Field of Classification Search

CPC ...... A61M 15/00; A61M 15/0003–001; A61M 15/002; A61M 15/0021; A61M 15/0028;

A61M 15/0033; A61M 15/0045; A61M 15/0051; A61M 15/0065; A61M 15/0085; A61M 15/0086–0088; A61M 15/06; A61M 15/08–085; A61M 11/00–005; (Continued)

(56) References Cited

U.S. PATENT DOCUMENTS

605,436 A 6/1898 Kellogg 642,748 A 2/1900 Manners

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1805730 A 7/2006 CN 101918061 A 12/2010 (Continued)

#### OTHER PUBLICATIONS

Cindy H. Dubin, *Nothing to Sneeze at*, Pharmaceutical Formulation & Quality Magazine (Jan. 29, 2003).

(Continued)

Primary Examiner — Michael J Tsai (74) Attorney, Agent, or Firm — Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

## (57) ABSTRACT

A method of delivering a substance, such as one or more of a triptan, a nasal steroid or carbon dioxide gas, to the nasal cavity of a subject, in particular for the treatment of headaches, for example, migraine, or rhinosinusitis, for example, chronic rhinosinusitis, optionally with polyps, the method comprising the steps of fitting a nosepiece to one nostril of the subject, delivering the substance through the nosepiece to the posterior region of the nasal cavity of the subject.

#### 22 Claims, 42 Drawing Sheets

